Probiotics and prebiotics in inflammatory bowel disease;Probióticos y prebióticos en la enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 30, Issue 7, 2007, Pages 419-425

  Borruel, Natalia ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; INTERLEUKIN 10; PREBIOTIC AGENT; PROBIOTIC AGENT;

ANIMAL MODEL; ARTICLE; BACTERIUM; ENTERITIS; HUMAN; IMMUNOREGULATION; INTESTINE FLORA; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; RAT; THERAPY EFFECT; ULCERATIVE COLITIS;

EID: 34548564074     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13108812     Document Type: Article

References (63)

1. Shanahan F. Crohn's disease. Lancet. 2002;359:62-9.
2. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-35.
3. Milner JA. Functional foods and health promotion. J Nutr. 1999;129:1395S-7S.
4. Guarner F, Schaafsma G. Probiotics. Int J Food Microbiol. 998;39:237-8.
5. Shanahan F. Probiotics in inflammatory bowel disease. Gut. 2001;48:609.
6. Shanahan F. Probiotics and inflammatory bowel disease:is there a scientific rationale? Inflamm Bowel Dis. 2000;6:107-15.
7. Stagg AJ, Hart AL, Knight SC, Kamm MA. Microbial-gut interactions in health and disease. Interactions between dendritic cells and bacteria in the regulation of intestinal immunity. Best Pract Res Clin Gastroenterol. 2004;18:255-70.
8. Allez M, Mayer L. Regulatory T cells: peace keepers in the gut. Inflamatory Bowel Diseases. 2004;10:666-76.
9. Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infection and Immunity. 2004;72:3299-309.
10. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602-9.
11. O'Mahony L, O'Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol. 2006;290:839-45.
12. Borruel N, Carol M, Casellas F, Antolin M, De Lara F, Espin E, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut. 2002;51:659-64.
13. Borruel N, Casellas F, Antolin M, Llopis M, Carol M, Espiin E, et al. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol. 2003;98:865-70.
14. Carol M, Borruel N, Antolin M, Llopis M, Casellas F, Guarner F, et al. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J Leukoc Biol. 2006;79:917-22.
15. Fabia R, Ar'Rajab A, Johansssib ML, Willen R, Andersson R. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic-acid induced colitis in the rat. Scand J Gastroenterol. 1993;28:155-62.
16. Mao Y, Nobaeck S, Kasravi B, Adawi D, Stenram U, Molin G, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 1996;111:334-44.
17. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10 deficient mice develop chronic enterocolitis. Cell. 1993;75:263-74.
18. Sellon RK, Tonkonogy SL, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10 deficient mice. Infect Immun. 1998;66:5224-31.
19. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology. 2000;118:1094-105.
20. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in Interleukin 10 gene-deficient mice. Gastroenterology. 1999;116:1107-14.
21. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-91.
22. Mccarthy J, O'Mahony, O'Callaghan L, Sheil B, Vaughan E, Fitzsimons N, et al. Double blind, placebo controlled trial of two probiotics strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975-80.
23. O'Mahony, Feeney M, O'Halloran S, Murphy l, Kiely B, Fitzgibbon J, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther. 2001;15:1219-25.
24. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun. 2006;74:4075-82.
25. Llopis M, Antolin M, Guarner F, Salas A, Malagelada JR. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut. 2005;54:955-9.
26. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis. 2002;8:71-80.
27. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut. 2003;52:370-6.
28. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine collitis by Lactococcus lactis secreting Interleukin-10. Science. 2000;289:1352-5.
29. Shanahan F. Turbo probiotics for IBD. Gastroenterology. 2001;120:1297-8.
30. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520-8.
31. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428-41.
32. Obermeier F, Dunger N, Strauch U, Grunwlad N, Herfarth H, Schölmerich J, et al. Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol. 2003;134:217-24.
33. Jijon H, Backer J, Díaz H, Yeung H, Thiel D, McKaigney C, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126:1358-73.
34. Reid G, Guarner F, Gibson G, Tompkins T, Gill H, Rowland I, et al; International Scientific Association for Probiotics and Prebiotics. Gastroenterology. 2004;127:366-7.
35. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697-8.
36. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-8.
37. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-9.
38. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-23.
39. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
40. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria- fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-41.
41. Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O'Donoghue D, Kiely B, and PROGID team of Investigators. A one year, randomised, double-blind, placebo controlled trial of a lactobacillus or a bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology. 2006;130:44A.
42. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-8.
43. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-46.
44. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderateulcerative colitis. Med Sci Monit. 2004;10:126-31.
45. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-74.
46. Malin M, Soumalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab. 1996:40:137-45.
47. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-7.
48. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005;11:833-9.
49. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997;25:653-8.
50. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5.
51. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-4.
52. Prantera C, Scribano ML, Falasco A, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405-9.
53. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842-7.
54. Van Gossum, Dewit O, Geboes K, et al. A randomized placebo-controlled clinical trial of probiotics (1. Jonhsonii, La1) on early endoscopic recrrence of Crohn's disease (CD) after ileocaecal resection. Gastroenterology. 2005;128 (4 Suppl 2): A17.
55. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlledtrial. Gastroenterology. 2000;119:305-9.
56. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-14.
57. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of puchitis onset with probiotic therapy: a double blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-9.
58. Kuhbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833-41.
59. Videla S, Vilaseca J, Antolín M, García-Lafuente A, Guarner F, Crespo E, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol. 2001;96:1486-93.
60. Schultz M, Munro K, Tannock GW, Melchner I, Gottl C, Schwietz H, et al. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immunol. 2004;11:581-7.
61. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA. Synbiotic therapy (Bifidobacterium longum/synergy 1) initiates resolution ofinflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-9.
62. Casellas F, Borruel N, Torrejón A, Varela E, Antolín M, Guarner F, et al. Prebiotic-improved response to mesalazine in mild ulcerative colitis. Gut. 2006;55 Suppl 5:122A.
63. Welters CF, Heineman E, Thunnissen FB, Van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002;45:621-7.